Close Menu

NEW YORK – T2 Biosystems said today that it has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services. Under the terms of the agreement, T2 Bio may receive up to $69 million to support further development of its portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes.

The agreement, described in a filing with the US Securities and Exchange Commission, was the first of three announcements today by the Lexington, Massachusetts-based diagnostics firm.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.